Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–82. https://doi.org/10.1097/j.pain.0000000000001939

Article  PubMed  PubMed Central  Google Scholar 

Palecek J, Paleckova V, Willis WD. The roles of pathways in the spinal cord lateral and dorsal funiculi in signaling nociceptive somatic and visceral stimuli in rats. Pain. 2002;96(3):297–307. https://doi.org/10.1016/S0304-3959(01)00459-6

Bannister K, Dickenson AH. The plasticity of descending controls in pain: translational probing. J Physiol. 2017;595(13):4159–4166. https://doi.org/10.1113/JP274165

Vase L, Wager TD, Eccleston C. Opportunities for chronic pain self-management: core psychological principles and neurobiological underpinnings. Lancet. 2025;405(10491):1781–1790. https://doi.org/10.1016/S0140-6736(25)00404-0

Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397(10289):2082–2097. https://doi.org/10.1016/S0140-6736(21)00393-7

American Society of Anesthesiologists Task Force on Chronic Pain Management. American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810–33. https://doi.org/10.1097/ALN.0b013e3181c43103

Article  Google Scholar 

Sokol R, Grossman E, Bourgery R. Nonopioid pharmacologic management of chronic noncancer pain. Am Fam Physician. 2025;112(2):187–96.

PubMed  Google Scholar 

Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R, CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States., 2022. MMWR Recomm Rep. 2022;71(3):1–95. https://doi.org/10.15585/mmwr.rr7103a1

Goodwin G, McMahon SB. The physiological function of different voltage-gated sodium channels in pain. Nat Rev Neurosci. 2021;22(5):263–74. https://doi.org/10.1038/s41583-021-00444-w

Article  PubMed  CAS  Google Scholar 

Chen R, Liu Y, Qian L, Yi M, Yin H, Wang S, Xiang B. Sodium channels as a new target for pain treatment. Front Pharmacol. 2025;16:1573254. https://doi.org/10.3389/fphar.2025.1573254

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alsaloum M, Higerd GP, Effraim PR, Waxman SG. Status of peripheral sodium channel blockers for non-addictive pain treatment. Nat Rev Neurol. 2020;16(12):689–705. https://doi.org/10.1038/s41582-020-00415-2

Article  PubMed  CAS  Google Scholar 

Lolignier S, Amsalem M, Maingret F, Padilla F, Gabriac M, Chapuy E, Eschalier A, Delmas P, Busserolles J. Nav1.9 channel contributes to mechanical and heat pain hypersensitivity induced by subacute and chronic inflammation. PLoS ONE. 2011;6(8):e23083. https://doi.org/10.1371/journal.pone.0023083

Article  PubMed  PubMed Central  CAS  Google Scholar 

Han C, Huang J, Waxman SG. Sodium channel Nav1.8: Emerging links to human disease. Neurology. 2016;86(5):473–83. https://doi.org/10.1212/WNL.0000000000002333

Article  PubMed  CAS  Google Scholar 

Klein AH, Vyshnevska A, Hartke TV, De Col R, Mankowski JL, Turnquist B, Bosmans F, Reeh PW, Schmelz M, Carr RW, Ringkamp M. Sodium Channel Nav1.8 Underlies TTX-Resistant Axonal Action Potential Conduction in Somatosensory C-Fibers of Distal Cutaneous Nerves. J Neurosci. 2017;37(20):5204–14.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Garrison SR, Weyer AD, Barabas ME, Beutler BA, Stucky CL. A gain-of-function voltage-gated sodium channel 1.8 mutation drives intense hyperexcitability of A- and C-fiber neurons. Pain. 2014;155(5):896–905. https://doi.org/10.1016/j.pain.2014.01.012. Epub 2014 Jan 18. PMID: 24447515; PMCID: PMC3989381.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Laird JM, Souslova V, Wood JN, Cervero F. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. J Neurosci. 2002;22(19):8352-6. https://doi.org/10.1523/JNEUROSCI.22-19-08352

Leo S, D’Hooge R, Meert T. Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav Brain Res. 2010;208(1):149–57.

Article  PubMed  CAS  Google Scholar 

Payne CE, Brown AR, Theile JW, Loucif AJ, Alexandrou AJ, Fuller MD, Mahoney JH, Antonio BM, Gerlach AC, Printzenhoff DM, Prime RL, Stockbridge G, Kirkup AJ, Bannon AW, England S, Chapman ML, Bagal S, Roeloffs R, Anand U, Anand P, Bungay PJ, Kemp M, Butt RP, Stevens EB. A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability. Br J Pharmacol. 2015;172(10):2654–70. https://doi.org/10.1111/bph.13092

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kort ME, Drizin I, Gregg RJ, Scanio MJ, Shi L, Gross MF, Atkinson RN, Johnson MS, Pacofsky GJ, Thomas JB, Carroll WA, Krambis MJ, Liu D, Shieh CC, Zhang X, Hernandez G, Mikusa JP, Zhong C, Joshi S, Honore P, Roeloffs R, Marsh KC, Murray BP, Liu J, Werness S, Faltynek CR, Krafte DS, Jarvis MF, Chapman ML, Marron BE. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J Med Chem. 2008;51(3):407–16. https://doi.org/10.1021/jm070637u

Article  PubMed  CAS  Google Scholar 

Banh C, Sic A, Knezevic NN. Sodium channel inhibitors in clinical development for pain management: a focused review. CNS Drugs. 2025 Nov 3. https://doi.org/10.1007/s40263-025-01244-x

Xie YF, Yang J, Ratté S, Prescott SA. Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs. Elife. 2024;12:RP90960. https://doi.org/10.7554/eLife.90960

Article  PubMed  PubMed Central  Google Scholar 

Stewart RG, Osorno T, Fujita A, Jo S, Ferraiuolo A, Carlin K, Bean BP. Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine. Proc Natl Acad Sci U S A. 2025;122(22):e2503570122. https://doi.org/10.1073/pnas.2503570122

Article  PubMed  PubMed Central  CAS  Google Scholar 

Browne LE, Clare JJ, Wray D. Functional and pharmacological properties of human and rat NaV1.8 channels. Neuropharmacology. 2009;56(5):905 – 14. https://doi.org/10.1016/j.neuropharm.2009.01.018

Pham A, Yep H, Wozniak S, Javvaji A, Nada E, Bergese S. Beyond Opioids: A Review of Suzetrigine for Acute Pain Management. Int J Mol Sci. 2025;26(20):9865. https://doi.org/10.3390/ijms26209865

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hemme J, Hijma PS, Siebenga ML, de Kam GJ, Groeneveld A. August Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults, Pain Medicine, 22, Issue 8, 2021, Pages 1814–26, https://doi.org/10.1093/pm/pnab032

Wu Z, Lu D. Advances in the discovery of selective NaV1.8 inhibitors for pain management. Eur J Med Chem. 2026;302(Pt 2):118326. https://doi.org/10.1016/j.ejmech.2025.118326.

Article  PubMed  CAS  Google Scholar 

Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A. 2007;104(20):8520–5. https://doi.org/10.1073/pnas.0611364104

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bertoch T, D’Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025;142(6):1085–99.

PubMed  PubMed Central  CAS  Google Scholar 

Attal N, Barrot M. Targeting Nav1.8 with the nonopioid antagonist suzetrigine for analgesia: cause for optimism? Br J Anaesth. 2025;135(4):829–32. https://doi.org/10.1016/j.bja.2025.07.043

Article  PubMed  PubMed Central  CAS  Google Scholar 

Karri J, D’Souza RS, Cohen SP. Between promise and peril: role of suzetrigine as a non-opioid analgesic. BMJ Med. 2025;4(1):e001431. https://doi.org/10.1136/bmjmed-2025-001431

Article  PubMed  PubMed Central  Google Scholar 

Bennett DL, Clark AJ, Huang J, Waxman SG, Dib-Hajj SD. The Role of Voltage-Gated Sodium Channels in Pain Signaling. Physiol Rev. 2019;99(2):1079–1151. https://doi.org/10.1152/physrev.00052.2017

Rajasingham R, Qi Y. Suzetrigine, a Non-Opioid Small-Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science. Clin Transl Sci. 2025;18(11):e70414. https://doi.org/10.1111/cts.70414

Article  PubMed  PubMed Central  CAS  Google Scholar 

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926. https://doi.org/10.1016/j.jpain.2009.06.012

Article  PubMed  PubMed Central